Ocata Therapeutics Inc fka OCAT

[Spetty772002]

ACT issued shares to stave off bankruptcy, and are now in the best financial position the company has ever been in. Had they not issued those shares, we wouldn't be having this conversation right now as there would be no more ACT. Besides the current clinical trials ACT is performing now for dry AMD, (which has a world-wide market potential of $25 billion), I don't think GERN has anything that can touch the ability to produce a potentially limitless supply of blood that can be given to anyone regardless of their blood type as well as vascular repair in people that have heart tissue that died due to heart failure. Go read the PR on the hemgioblast program and do some DD on it. ACT also has other exciting treatments in their pipeline as well. This video is a great overview of the company, their programs etc. Take a few minutes and watch it.

http://www.youtube.com/user/eigenman40#p/a/u/2/MPBiNlUFIww

I'm not sure what your goal is here, but one thing is clear: you know nothing about ACT other than their share count. Watch the video I provided and go do some DD and then come back when you can have a reasonable debate without issuing blanket statements which evidence you have no clue as to what you're talking about.

For the record, if embryonic stem cells DO work, IMO ACT will receive FDA approval and will be the first to market with the first embryonic stem cell treatment long before GERN will simply due to the fact that success or failure in the eyes should become evident much more quickly than will success or failure in a crushed spine. We should start getting some preliminary results within the next 3 months or so on their current trials for AMD/Stargardt's. If all goes as well as expected, ACTC may be able to terminate the Phase I/II trial early (not right after the prelim results but maybe after a year instead of 2 years) and head straight to Phase III, and if Phase III goes well they would likely be fast-tracked for FDA review...